rawfin.tv
Vaxart Targets H1 2027 for Phase IIb COVID-19 Data with BARDA Support
MarketsstocksAI Generated

Vaxart Targets H1 2027 for Phase IIb COVID-19 Data with BARDA Support

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Vaxart Inc. announced plans to release top-line data from its Phase IIb COVID-19 vaccine trial in the first half of 2027. The development is supported by funding from the Biomedical Advanced Research and Development Authority (BARDA).

BiotechPharmaceuticalsCOVID-19Clinical TrialsHealthcare

Related Articles

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

stocks
S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks